Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25039895 | 0.80 | NPC1 (0.43) | KDM4EKMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL3373962 | 0.80 | KDM4E (0.69) | KDM4EKMT2AHTR4CYP3A4CYP2D6 | |
| SCHEMBL25037576 | 0.79 | KDM4E (0.59) | KDM4EKMT2AHTR4CYP3A4CYP2D6 | |
| SCHEMBL25039191 | 0.78 | KDM4E (0.58) | KDM4EKMT2AHTR4CYP3A4CYP2D6 | |
| SCHEMBL25040521 | 0.78 | KMT2A (0.51) | KMT2ACYP3A4MEN1 | |
| SCHEMBL18373610 | 0.77 | KDM4E (0.56) | KDM4EKMT2AHTR4CYP3A4CYP2D6 | |
| SCHEMBL11404760 | 0.76 | KDM4E (0.79) | KDM4EKMT2ACYP3A4TSHRGAA | |
| SCHEMBL372600 | 0.76 | KDM4E (1.00) | KDM4EKMT2ATSHRGAAGLA | |
| SCHEMBL31408659 | 0.76 | KDM4E (1.00) | KDM4EKMT2ATSHRGAAGLA | |
| SCHEMBL8788521 | 0.75 | KDM4E (0.61) | KDM4EKMT2AHTR4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | KDM4E 1437/4885KMT2A 3652/4885HTR4 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.